创伤性脑损伤后的肾功能不全:病理生理与一般管理
本文综述创伤性脑损伤(TBI)入住ICU患者急性肾损伤(AKI)的流行病学与病理生理:近半数TBI患者入住ICU,其中10%发生AKI、2%需肾脏替代治疗(KRT)。降低颅内压(ICP)与优化脑灌注压(CPP)仍是核心治疗目标,甘露醇与高渗盐水均与AKI风险增加相关,甘露醇可能更高。以晶体液和血管活性药为基础的血流动力学管理宜由血流动力学监测指导,盐水基溶液有高氯血症风险、可能危及肾功能,高危患者可建议频繁监测血清氯。需KRT的少数患者依据病理生理与专家意见建议采用连续技术,启动时尤其必须精确监测ICP与CPP。
要点
- 近半数TBI患者入住ICU,其中10%发生AKI、2%需KRT。
- 甘露醇与高渗盐水均与AKI风险增加相关,甘露醇的风险可能高于高渗盐水。
- 低渗白蛋白或晶体液复苏可能增加脑水肿风险;盐水基溶液有高氯血症风险、可能危及肾功能。
- 高危患者可建议频繁评估血清氯;个体化CPP目标是否获益需进一步研究。
- 需KRT的少数TBI患者依据病理生理与专家意见建议采用连续技术,启动时尤其必须精确监测ICP与CPP。
适用人群与场景
- 入住ICU的创伤性脑损伤(TBI)患者,尤其是存在AKI风险或已发生AKI者。
- 需要KRT的少数TBI患者。
处置流程与药物剂量
- 严重TBI管理以预防继发性脑损伤为基石,降低ICP与优化CPP仍是重要治疗目标。
- 治疗ICP升高发作时经常使用甘露醇和高渗盐水等渗透性药物;两者均与AKI风险增加相关,甘露醇的风险可能高于高渗盐水。
- 血流动力学管理联合使用血管内容量液体与血管活性药,理想情况下由血流动力学监测指导。
- 避免使用低渗白蛋白或晶体液复苏溶液以免增加脑水肿风险;盐水基溶液经常使用但有高氯血症风险、可能危及肾功能,高危患者可建议频繁评估血清氯。
- 维持足够CPP包括优化循环血容量,常联合血管活性药物。
- 需KRT的少数TBI患者,依据病理生理与专家意见建议采用连续技术;启动KRT时尤其必须精确监测ICP与CPP。
红旗征与不能漏的情况
- KRT需求与颅内高压风险升高相关,尤其当渗透性清除发生较快时,连续技术中也可能发生。
研究设计与关键结果
- 本综述概述入住ICU的TBI患者AKI的流行病学与病理生理:近半数TBI患者入住ICU,其中10%发生AKI、2%需KRT。
- 目前缺乏针对TBI合并AKI患者的临床试验;正在等待比较甘露醇与高渗盐水的前瞻性随机对照试验结果。
- 基于脑血管自动调节监测的个体化CPP目标是否有益需进一步研究;类似的个体化灌注目标也正在慢性高血压患者中作为减轻AKI风险的策略进行研究。
证据类型、等级与局限
- 证据类型:综述。
- 依据病理生理与专家意见,需KRT的少数TBI患者建议采用连续技术。
- 局限:原文未报告局限性。
对床旁实践的改变
- TBI患者使用甘露醇或高渗盐水降ICP时,应认识到两者均与AKI风险增加相关,甘露醇可能更高。
- 使用盐水基溶液时,高危患者可建议频繁评估血清氯。
- 需KRT的TBI患者依据病理生理与专家意见建议采用连续技术,并在启动时尤其精确监测ICP与CPP。
- 基于脑血管自动调节监测的个体化CPP目标是否有益需进一步研究,暂不能作为常规推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Traumatic brain injury (TBI) remains a major cause of mortality and morbidity, and almost half of these patients are admitted to the intensive care unit. Of those, 10% develop acute kidney injury (AKI) and 2% even need kidney replacement therapy (KRT). Although clinical trials in patients with TBI who have AKI are lacking, some general principles in this population may apply. The present review is an overview on the epidemiology and pathophysiology of AKI in patients with TBI admitted to the intensive care unit who are at risk for or who have developed AKI. A cornerstone in severe TBI management is preventing secondary brain damage, in which reducing the intracranial pressure (ICP) and optimizing the cerebral perfusion pressure (CPP) remain important therapeutic targets. To treat episodes of elevated ICP, osmolar agents such as mannitol and hypertonic saline are frequently administered. Although we are currently awaiting the results of a prospective randomized controlled trial that compares both agents, it is important to realize that both agents have been associated with an increased risk of developing AKI which is probably higher for mannitol compared with hypertonic saline. For the brain, as well as for the kidney, targeting an adequate perfusion pressure is important. Hemodynamic management based on the combined use of intravascular fluids and vasopressors is ideally guided by hemodynamic monitoring. Hypotonic albumin or crystalloid resuscitation solutions may increase the risk of brain edema, and saline-based solutions are frequently used but have a risk of hyperchloremia, which might jeopardize kidney function. In patients at risk, frequent assessment of serum chloride might be advised. Maintenance of an adequate CPP involves the optimization of circulating blood volume, often combined with vasopressor agents. Whether individualized CPP targets based on cerebrovascular autoregulation monitoring are beneficial need to be further investigated. Interestingly, such individualized perfusion targets are also under investigation in patients as a strategy to mitigate the risk for AKI in patients with chronic hypertension. In the small proportion of patients with TBI who need KRT, continuous techniques are advised based on pathophysiology and expert opinion. The need for KRT is associated with a higher risk of intracranial hypertension, especially if osmolar clearance occurs fast, which can even occur in continuous techniques. Precise ICP and CPP monitoring is mandatory, especially at the initiation of KRT.
参考来源
- De Vlieger G, Meyfroidt G. Kidney Dysfunction After Traumatic Brain Injury: Pathophysiology and General Management. Neurocrit Care. 2022. PMID: 36324003. doi:10.1007/s12028-022-01630-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。